國家衛生研究院 NHRI:Item 3990099045/11183
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906632      Online Users : 958
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11183


    Title: Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients – A Taiwanese study
    Authors: Wu, TH;Lee, LJH;Yuan, CT;Chen, TWW;Yang, JCH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: Background/Purpose: There are scarce reports on the prognostic factors and treatment outcomes of patients with malignant pleural mesothelioma (MPM) in Asia. This study aimed to address these matters in a real-world setting. Methods: Medical records of patients with histologically proven MPM diagnosed between 1977 and 2016 at the National Taiwan University Hospital were reviewed. Variables including age, gender, performance status, asbestos exposure, smoking history, histology subtype, staging, and treatment received were recorded. All patients were followed until death or March 1st, 2017. Survival and prognostic factors were analyzed by the Kaplan-Meir method and the Cox proportional hazard model. Results: A total of 93 patients was identified, including 65 men and 28 women. An increasing trend of MPM cases diagnosed was observed in the past 40 years. Stage I/II disease (HR 0.24, 95% CI 0.13–0.46) and epithelioid histology (HR 0.42, 95% CI 0.23–0.75) were associated with favorable prognosis, whereas age ≥70 years (HR 2.66, 95% CI 1.36–5.22) and ECOG ≥2 (HR 5.03, 95% CI 2.69–9.4) were poor prognostic factors. After adjustment for prognostic factors, surgery in stage I-III MPM (HR 0.36, 95% CI 0.15–0.83) and systemic therapy in stage III/IV disease (HR 0.42, 95% CI 0.19–0.94) conferred a survival benefit. Conclusion: This is one of the largest case series of MPM reported in Asia outside of Japan. Prognostic factors in the study population included age, performance status, stage, and histology subtype. Surgery in potentially resectable disease and systemic therapy in advanced MPM confer a survival benefit in Asian patients.
    Date: 2019-01
    Relation: Journal of the Formosan Medical Association. 2019 Jan;118(1 Pt.2):230-236.
    Link to: http://dx.doi.org/10.1016/j.jfma.2018.04.001
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0929-6646&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000455212200004
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85046116513
    Appears in Collections:[Lukas Jyuhn-Hsiarn Lee] Periodical Articles

    Files in This Item:

    File SizeFormat
    SCP85046116513.pdf516KbAdobe PDF324View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback